Antiviral resistance mutations potentiate hepatitis B virus immune evasion through disruption of its surface antigen a determinant

Antiviral Therapy

Volumn 13, Issue 3, 2008, Pages 439-447

  Sloan, Richard D ^a,b,c   Ijaz, Samreen ^a   Moore, Penny L ^b,d   Harrison, Tim J ^c   Teo, Chong Gee ^a,e   Tedder, Richard S ^a,b  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c MCGILL UNIVERSITY   (Canada)

^d NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; AMINO ACID; ANTIVIRUS AGENT; ENTECAVIR; EPITOPE; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; ADENINE; DRUG DERIVATIVE; GUANINE; HEPATITIS B ANTIBODY; P PROTEIN, HEPATITIS B VIRUS; PHOSPHONIC ACID DERIVATIVE; POL PROTEIN;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANTIGEN ANTIBODY REACTION; ANTIVIRAL RESISTANCE; ARTICLE; CHO CELL; CODON; COMPREHENSION; FEMALE; GENETIC TRANSFECTION; HEPATITIS B VIRUS; IMMUNIZATION; IMMUNOREACTIVITY; MUTATION; NONHUMAN; PLASMID; PRIORITY JOURNAL; VIRUS GENE; VIRUS IMMUNITY; ANIMAL; CRICETULUS; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; EPITOPE MAPPING; GENE EXPRESSION REGULATION; GENETICS; HAMSTER; HUMAN; IMMUNOLOGY; MULTIDRUG RESISTANCE; SITE DIRECTED MUTAGENESIS;

ADENINE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN-ANTIBODY REACTIONS; ANTIVIRAL AGENTS; CHO CELLS; CRICETINAE; CRICETULUS; DRUG RESISTANCE, MULTIPLE, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, VIRAL; GENE PRODUCTS, POL; GUANINE; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNODOMINANT EPITOPES; LAMIVUDINE; MUTAGENESIS, SITE-DIRECTED; MUTATION; PHOSPHONIC ACIDS; TRANSFECTION;

EID: 47249117068     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337:1733-1745.
2. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988; 61:1942-1956.
3. Evans AA & London WT. Epidemiology of hepatitis B. In Viral Hepatitis. Edited by AJ Zuckerman & HC Thomas. London: Harcourt Brace and Company Limited 1998; pp. 107-114.
4. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65-73.
5. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339:61-68.
6. Wright TL. Clinical trial results and treatment resistance with lamivudine in hepatitis B. Semin Liver Dis 2004; 24:31-36.
7. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352:2673-2681.
8. Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004; 48:3498-3507.
9. Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006; 130:2039-2049.
10. Chang TT, Gish RG, Hadziyannis SG, et al. A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005; 129:1198-1209.
11. Ling R, Harrison TJ. Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus. J Gen Virol 1999; 80:601-606.
12. Delaney WE IV, Yang H, Westland CE, et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 2003; 77:11833-11841.
13. Osiowy C, Villeneuve JP, Heathcote EJ, et al. Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2). J Clin Microbiol 2006; 44:1994-1997.
14. Villet S, Ollivet A, Pichoud C, et al. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol 2007; 46:531-538.
15. Ngui SL, Hallet R, Teo CG. Natural and iatrogenic variation in hepatitis B virus. Rev Med Virol 1999; 9:183-209.
16. Tipples GA, Ma MM, Fischer KP, et al. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24:714-717.
17. Bartholomew MM, Jansen RW, Jeffers LJ, et al. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotropic liver transplantation. Lancet 1997; 349:20-22.
18. Terrault NA, Zhou S, McCory RW, et al. Incidence and clinical consequences of surface and polymerase mutations in liver transplant recipients on hepatitis B immunoglobulin. Hepatology 1998; 28:555-561.
19. Ogura Y, Kurosaki M, Asahini Y et al. Prevalence and significance of naturally occurring mutations in the surface and polymerase genes of hepatitis B virus. J Infect Dis 1999; 180:1444-1451.
20. Shields PL, Owsianka A, Carman WF, et al. Selection of hepatitis B surface 'escape' mutants during passive immune prophylaxis following liver transplantation: potential impact of genetic changes on polymerase protein function. Gut 1999; 45:306-309.
21. Torresi J, Earnest-Silveira L, Deliyannis G, et al. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 2002; 293:305-313.
22. Torresi J, Earnest-Silveira L, Civitico G, et al. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the 'fingers' subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. Virology 2002; 299:88-99.
23. Ijaz S, Ferns RB, Tedder RS. A 'first loop' linear epitope accessible on native hepatitis B surface antigen that persists in the face of second loop immune escape. J Gen Virol 2003; 84:269-275.
24. Tedder RS, Guarascio P, Yao JL, et al. Production of monoclonal antibodies to hepatitis B surface and core antigens, and use in the detection of viral antigens in liver biopsies. J Hyg (Lond) 1983; 90:135-142.
25. Chen YC, Delbrook K, Dealwis C, et al. Discontinuous epitopes of hepatitis B surface antigen derived from a filamentous phage peptide library. Proc Natl Acad Sci U S A 1996; 93:1997-2001.
26. Prange R, Streek RE. Novel transmembrane topology of the hepatitis B virus envelope proteins. EMBO J 1995; 14:247-256.
27. Paulij WP, de Wit PL, Sunnen CM, et al. Localization of a unique hepatitis B virus epitope sheds new light on the structure of hepatitis B virus surface antigen. J Gen Virol 1999; 80:2121-2126.
28. Jolivet-Reynaud C, Lesenechal M, O'Donnell B, et al. Localization of hepatitis B surface antigen epitopes present on variants and specifically recognised by anti-hepatitis B surface antigen monoclonal antibodies. J Med Virol 2001; 65:241-249.
29. Kiire CF. The epidemiology and prophylaxis of hepatitis B in sub-Saharan Africa: a view from tropical and subtropical Africa. Gut 1996; 38:S5-S12.
30. Sheldon J, Ramos B, Garcia-Samaniego J, et al. Selection of hepatitis B Virus (HBV) vaccine escape mutants in HBV-infected and HBV/HIV-coinfected patients failing antiretroviral drugs with anti-HBV activity. J Acquir Immune Defic Syndr [Epub ahead of print].
31. Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36:687-696.
32. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998; 27:628-633.
33. Carman WF, Zanetti AR, Karayiannis P, et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990; 336:325-329.